Endometriosis

Pelvic, Dysmenorrhea Pain Sustained Relief With Elagolix

Pelvic, Dysmenorrhea Pain Sustained Relief With Elagolix

By

Treatment with elagolix was associated with sustained reduction in average monthly dysmenorrhea and non-menstrual pelvic pain through a 12-month treatment period.

Ethinylestradiol Drospirenone Combination May Alleviate Endometriosis-Related Pain

Ethinylestradiol Drospirenone Combination May Alleviate Endometriosis-Related Pain

By

A flexible extended regimen of 20 mg ethinylestradiol and 3 mg drospirenone (FlexibleMIB) was shown to be superior to placebo for reducing endometriosis-related pain.

Elagolix May Be Effective for Reducing Pain From Endometriosis

Elagolix May Be Effective for Reducing Pain From Endometriosis

By

At 3 months, significantly more women receiving both doses of elagolix had reductions in dysmenorrhea and nonmenstrual pelvic pain compared with those receiving placebo.

Chronic Pelvic Pain Not Sufficiently Explained by Presence of Endometriosis

Chronic Pelvic Pain Not Sufficiently Explained by Presence of Endometriosis

By

Women with chronic pelvic pain had greater connectivity in "pain" regions of the brain, regardless of presence of endometriosis.

Sign Up for Free e-Newsletters